Augmented Reality enables the physical environment or object to become a digital portal to relevant, person...
In this issue of Clinical Watch, we highlight the NIH Panel recommendations regarding medications associated with COVID-19 treatment and suggest prior authorization criteria for the first approved tre
In this issue of Clinical Watch, we highlight aspects of Medicaid programs that are affected COVID-19 and suggest prior authorization criteria for a new lipid-lowering drug.
Pharmaceutical manufacturers and payers are often at odds over pricing and barriers to new medication access. Payers will typically initiate a variety of cost containment initiatives,
In this issue of Clinical Watch, we discuss COVID-19 and suggest prior authorization criteria for immunotherapy to reduce the severity of allergic reactions to peanuts.
Augmented Reality enables the physical environment or object to become a digital portal to relevant, personalized information that can be tailored to inform users...
In this issue of Clinical Watch, we discuss the expanded indication for drugs to treat relapsing forms of multiple sclerosis.
Yet the process of getting patients going on medications through a PAP is often slowed or inhibited by the information-gathering process...
Big data has the ability to transform pharma field sales — if pharma manufacturers can translate data into actionable insights and real-time outreach at the individual territory level.
Telemedicine offers new strategies to improve Medicaid programs
In this issue of Clinical Watch, we discuss the FDA guidance on biosimilar interchangeability.
In a recent press release, Conduent announced it was named an overall leader in NelsonHall’s Advanced Analytics NEAT Rankings across multiple industries, including healthcare.
Conduent was recognized as a leader in the NelsonHall Healthcare Commercial Payer BPS report, which examines BPS activities associated with healthcare insurance in the commercial sector in the United
In this issue of Clinical Watch, we discuss the evolution of psoriasis treatment. We suggest criteria for a new biologic for plaque psoriasis and review the albumin-lowering effect of dapagliflozin.
How do you measure quality in healthcare? It's a question that is top of mind in an industry where quality is both expected and difficult to define.
The FDA is encouraging the industry to include patients in a meaningful way in drug development — from pre-IND through commercialization.